1.68
price up icon0.00%   0.00
after-market Dopo l'orario di chiusura: 1.71 0.03 +1.79%
loading
Precedente Chiudi:
$1.68
Aprire:
$1.68
Volume 24 ore:
1.38M
Relative Volume:
1.54
Capitalizzazione di mercato:
$181.91M
Reddito:
$27.08M
Utile/perdita netta:
$-37.00M
Rapporto P/E:
-3.2308
EPS:
-0.52
Flusso di cassa netto:
$-18.46M
1 W Prestazione:
+5.66%
1M Prestazione:
+10.53%
6M Prestazione:
-33.07%
1 anno Prestazione:
+21.74%
Intervallo 1D:
Value
$1.64
$1.78
Intervallo di 1 settimana:
Value
$1.58
$1.78
Portata 52W:
Value
$1.05
$5.17

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Name
Nome
Aclaris Therapeutics Inc
Name
Telefono
484-324-7933
Name
Indirizzo
701 LEE ROAD, WAYNE, PA
Name
Dipendente
64
Name
Cinguettio
@aclaristx
Name
Prossima data di guadagno
2025-02-24
Name
Ultimi documenti SEC
Name
ACRS's Discussions on Twitter

Confronta ACRS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ACRS
Aclaris Therapeutics Inc
1.68 181.91M 27.08M -37.00M -18.46M -0.52
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-10 Ripresa Piper Sandler Overweight
2025-05-28 Iniziato Wedbush Outperform
2025-03-18 Ripresa Cantor Fitzgerald Overweight
2024-12-23 Aggiornamento H.C. Wainwright Neutral → Buy
2024-11-20 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2024-11-19 Aggiornamento BTIG Research Neutral → Buy
2024-11-19 Aggiornamento Jefferies Hold → Buy
2024-11-19 Aggiornamento Leerink Partners Market Perform → Outperform
2024-11-18 Aggiornamento Piper Sandler Neutral → Overweight
2024-01-22 Downgrade H.C. Wainwright Buy → Neutral
2023-11-13 Downgrade William Blair Outperform → Mkt Perform
2023-10-03 Iniziato Evercore ISI Outperform
2022-12-14 Iniziato Stifel Buy
2022-12-01 Iniziato Goldman Buy
2022-10-06 Iniziato BTIG Research Buy
2021-07-23 Ripresa Jefferies Buy
2021-06-15 Iniziato Piper Sandler Overweight
2021-04-21 Iniziato H.C. Wainwright Buy
2019-10-22 Aggiornamento SVB Leerink Mkt Perform → Outperform
2019-09-06 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2019-06-27 Downgrade SVB Leerink Outperform → Mkt Perform
2019-05-06 Iniziato SVB Leerink Outperform
2018-03-28 Ripresa Leerink Partners Outperform
2018-02-09 Iniziato Guggenheim Buy
2017-06-16 Iniziato Cantor Fitzgerald Overweight
2016-11-29 Iniziato Leerink Partners Outperform
2016-09-30 Iniziato JMP Securities Mkt Outperform
2016-06-10 Iniziato Guggenheim Buy
2015-11-02 Iniziato Citigroup Buy
2015-11-02 Iniziato Jefferies Buy
Mostra tutto

Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie

pulisher
Jul 24, 2025

What analysts say about Aclaris Therapeutics Inc. stockFree Predictions - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

What institutions are buying Aclaris Therapeutics Inc. stock nowFree Stock Market Knowledge Sharing - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

LENZ Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital appreciation - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Aclaris Therapeutics Inc. stock priceFree Consultation - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Aclaris Therapeutics Inc. Stock Analysis and ForecastTremendous financial leverage - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Aclaris Therapeutics Inc. a good long term investmentRapid capital growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

How Aclaris Therapeutics Inc. stock performs during market volatilityStrong Return Daily Alerts - Newser

Jul 22, 2025
pulisher
Jul 15, 2025

Why Aclaris Therapeutics Inc. stock attracts strong analyst attentionGroup Only Stock Signals - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Aclaris Therapeutics Inc. stock price move sharplyEntry Level Low Risk Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey

Jul 15, 2025
pulisher
Jul 12, 2025

Piper Sandler Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS) - Defense World

Jul 12, 2025
pulisher
Jul 11, 2025

Aclaris Therapeutics' Recent Gains Improve Losses On Insider Purchases Worth US$1.50m - simplywall.st

Jul 11, 2025
pulisher
Jul 10, 2025

Plus Therapeutics (NASDAQ:PSTV) vs. Aclaris Therapeutics (NASDAQ:ACRS) Head-To-Head Survey - Defense World

Jul 10, 2025
pulisher
Jul 07, 2025

Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN

Jul 07, 2025
pulisher
Jul 07, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Jul 07, 2025
pulisher
Jun 30, 2025

Aclaris Therapeutics at HCW Conference: Strategic Moves and Future Plans By Investing.com - Investing.com Canada

Jun 30, 2025
pulisher
Jun 30, 2025

Aclaris Therapeutics joins Russell 3000 and Russell 2000 indexes - Investing.com

Jun 30, 2025
pulisher
Jun 30, 2025

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes - GlobeNewswire

Jun 30, 2025
pulisher
Jun 30, 2025

Aclaris Added to Russell Indexes: $10.6T in Benchmark Assets Now Track Biotech Stock - Stock Titan

Jun 30, 2025
pulisher
Jun 30, 2025

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Small Cap Completeness Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Aclaris Therapeutics joins Russell 3000 and Russell 2000 indexes By Investing.com - Investing.com UK

Jun 30, 2025
pulisher
Jun 27, 2025

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference - The Manila Times

Jun 27, 2025
pulisher
Jun 26, 2025

Aclaris Therapeutics to Present at H.C. Wainwright Inflammation & Immunology Virtual Conference on June 30, 2025 - Nasdaq

Jun 26, 2025
pulisher
Jun 26, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Receives “Buy” Rating from HC Wainwright - Defense World

Jun 26, 2025
pulisher
Jun 25, 2025

Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 - MSN

Jun 25, 2025
pulisher
Jun 24, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Given Outperform Rating at Wedbush - Defense World

Jun 24, 2025
pulisher
Jun 19, 2025

Assenagon Asset Management S.A. Purchases 284,191 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Jun 19, 2025
pulisher
Jun 15, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $9.71 Consensus Price Target from Analysts - Defense World

Jun 15, 2025
pulisher
Jun 12, 2025

Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 26% - simplywall.st

Jun 12, 2025
pulisher
Jun 11, 2025

Aclaris at Goldman Sachs Conference: Strategic Focus on Immuno-inflammatory Pipeline By Investing.com - Investing.com South Africa

Jun 11, 2025
pulisher
Jun 11, 2025

Aclaris at Goldman Sachs Conference: Strategic Focus on Immuno-inflammatory Pipeline - Investing.com Australia

Jun 11, 2025

Aclaris Therapeutics Inc Azioni (ACRS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):